immatics biotechnologies GmbH Statistics
Share Statistics
immatics biotechnologies GmbH has 2.83B shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 2.83B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -7.91 and the forward PE ratio is null.
| PE Ratio | -7.91 |
| Forward PE | null |
| PS Ratio | 14.21 |
| Forward PS | null |
| PB Ratio | 3.41 |
| P/FCF Ratio | -60.28 |
| PEG Ratio | n/a |
Enterprise Valuation
immatics biotechnologies GmbH has an Enterprise Value (EV) of 564.26M.
| EV / Earnings | -5.82 |
| EV / Sales | 10.45 |
| EV / EBITDA | -6.35 |
| EV / EBIT | -5.55 |
| EV / FCF | -44.33 |
Financial Position
The company has a current ratio of 2.87, with a Debt / Equity ratio of 0.
| Current Ratio | 2.87 |
| Quick Ratio | 2.87 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -122.41 |
Financial Efficiency
Return on equity (ROE) is -0.43% and return on capital (ROIC) is -42.3%.
| Return on Equity (ROE) | -0.43% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -42.3% |
| Revenue Per Employee | 99.63K |
| Profits Per Employee | -178.96K |
| Employee Count | 542 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 118.66M |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.78, so immatics biotechnologies GmbH's price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 2.44 |
| Relative Strength Index (RSI) | 40.28 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, immatics biotechnologies GmbH had revenue of 54.00M and earned -96.99M in profits. Earnings per share was -1.2.
| Revenue | 54.00M |
| Gross Profit | -64.67M |
| Operating Income | -101.72M |
| Net Income | -96.99M |
| EBITDA | -88.93M |
| EBIT | -101.72M |
| Earnings Per Share (EPS) | -1.2 |
Balance Sheet
The company has 218.47M in cash and 15.40M in debt, giving a net cash position of 203.07M.
| Cash & Cash Equivalents | 218.47M |
| Total Debt | 15.40M |
| Net Cash | 203.07M |
| Retained Earnings | -597.29M |
| Total Assets | 577.23M |
| Working Capital | 383.87M |
Cash Flow
In the last 12 months, operating cash flow was 18.23M and capital expenditures -30.96M, giving a free cash flow of -12.73M.
| Operating Cash Flow | 18.23M |
| Capital Expenditures | -30.96M |
| Free Cash Flow | -12.73M |
| FCF Per Share | -0.16 |
Margins
Gross margin is -11.98K%, with operating and profit margins of -18.84K% and -17.96K%.
| Gross Margin | -11.98K% |
| Operating Margin | -18.84K% |
| Pretax Margin | -17.96K% |
| Profit Margin | -17.96K% |
| EBITDA Margin | -164.69% |
| EBIT Margin | -188.39% |
| FCF Margin | -23.57% |
Dividends & Yields
IMTXW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for IMTXW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 1.63 |
| Piotroski F-Score | 4 |